ANTIPSYCHOTICS PRIOR AUTHORIZATION FORM





(form effective 1/6/2025)

Fax to PerformRx SM at **1-888-981-5202**, or to speak to a representative, call **1-866-610-2774**.

PRIOR AUTHORIZATION R	EQUEST INFORMATIO	N					
☐ New request ☐ Renewal reques	t Total pages:	Total pages: Office contact/phone:			LTC facility contact/phone:		
DATIENT INCORMATION				1			
PATIENT INFORMATION Patient name:			Patient ID#:		DOB:		
Street address:		Apt :		City/state/zip:	DOB.		
		A	φι #.	Oity/State/Zip.			
PRESCRIBER INFORMATIO	N						
Prescriber name:			T				
Specialty:			NPI:	T	State license #:		
Street address:		S	Suite #:	City/state/zip:			
Phone:			Fax:				
MEDICATION REQUESTED							
Preferred Agents							
Non-Injectable							
☐ Aripiprazole Tablet	☐ Haloperidol Tablet	•		e Tablet	☐ Risperidone Solution		
☐ Clozapine Tablet	•	☐ Haloperidol Lactate Oral		ne ER Tablet	☐ Risperidone Tablet		
☐ Equetro (carbamazepine) Capsule ☐ Fluphenazine Oral Concentrate Soluti		Concentrate Solution		ine Tablet Tablet	☐ Trifluoperazine Tablet ☐ Ziprasidone Capsule		
☐ Fluphenazine Tablet	□ Lurasidone Tablet	☐ Loxapine Capsule		ER Tablet			
Injectable			duotiapino	LIT IUDIOL			
☐ Abilify Asimtufii (aripiprazole)	☐ Fluphenazine Decan	oate Vial	☐ Haloperid	ol Lactate Vial	☐ Perseris ER (risperidone)		
☐ Abilify Maintena (aripiprazole)	•	☐ Haloperidol Decanoate Ampule		fyera (paliperidone)	☐ Risperdal Consta (risperidone)		
☐ Aristada ER (aripiprazole lauroxil)	☐ Haloperidol Decanoa	☐ Haloperidol Decanoate Vial		stenna (paliperidone)	☐ Rykindo (risperidone) Vial		
☐ Aristada Initio (aripiprazole lauroxil)	☐ Haloperidol Lactate :	☐ Haloperidol Lactate Syringe		nza (paliperidone)	☐ Uzedy ER (risperidone)		
Strength:	Dosage form:		Directions:				
Diagnosis:							
Non-Preferred Agents							
Non-Injectable							
☐ Abilify (aripiprazole) Tablet	☐ Clozaril (clozapine) Ta	ablet	□ Olanzapin	e ODT	☐ Seroquel XR (quetiapine) Tablet		
☐ Abilify Mycite (aripiprazole tablet +	☐ Fanapt (iloperidone)	Tablet	☐ Olanzapin	e-Fluoxetine Capsule	☐ Symbyax (olanzapine-fluoxetine) Capsule		
sensor)	☐ Fluphenazine Elixir		□ Perphenaz	ine-Amitriptyline Table	t □ Thioridazine Tablet		
☐ Adasuve (loxapine) Inhalation Powde			☐ Pimozide ¯		☐ Thiothixene Capsule		
☐ Aripiprazole ODT	☐ Invega ER (paliperido			expiprazole) Tablet	☐ Versacloz (clozapine) Suspension		
☐ Aripiprazole Solution	☐ Latuda (lurasidone) T			(risperidone) Solution	☐ Vraylar (cariprazine) Capsule		
☐ Asenapine SL Tablet	☐ Lybalvi (olanzapine/s	amidorphan) lablei		(risperidone) Tablet	☐ Zyprexa (olanzapine) Tablet		
☐ Caplyta (lumateperone) Capsule☐ Chlorpromazine Concentrate Solution	☐ Molindone Tablet☐ Nuplazid (pimavanse	rin) Cancula	☐ Risperidor	. (asenapine) Tablet	☐ Zyprexa (olanzapine) Zydis		
☐ Chlorpromazine Concentrate Solution	☐ Nuplazid (pimavanse			asenapine) Patch			
☐ Clozapine ODT	□ Nuplazia (piinavanse	iii) iabict		guetiapine) Tablet			
Injectable				1			
☐ Chlorpromazine Ampule	☐ Geodon (ziprasidone)	Vial	☐ Risperidor	e ER Vial	☐ Zyprexa Relprevy (olanzapine)		
☐ Chlorpromazine Vial	☐ Haldol Decanoate (ha		☐ Ziprasidon		☐ Zyprexa (olanzapine) Vial		
☐ Fluphenazine HCl Vial	☐ Olanzapine Vial	, ,			7,		
Strength:	Dosage form:		Directions:				
Diagnosis:			'				
PHARMACY INFORMATION	(Prescriber to identif	v the pharma	cy that is to e	isnansa tha mas	dication).		
				ispense the met	dication).		
Deliver to: Patient's Home Physician's Office Patient's Preferred Pharmacy Name:							
Pharmacy Phone #: Pharmacy Fax #:							
☐ I acknowledge that the patient agrees with the pharmacy chosen for delivery of this medication.							
REQUEST FOR A NON-PREFERRED AGENT							
Has the patient taken the requested r	<u> </u>	· · · · · · · · · · · · · · · · · · ·					
2. Has the patient tried and failed the pr	2. Has the patient tried and failed the preferred medications (listed above)? Yes – List medications tried:						
3. Does the patient have a contraindication or intolerance to the preferred medications? Yes – Submit documentation of contraindication/intolerance. No							



REQUEST FOR A PATIENT LESS THAN 18 YEARS OF AGE	
4. For renewal requests, has the patient had improvement in target symptoms with use of this medication? \square Yes \square No	
5. Is this request for a dose increase of a previously approved medication or request over the plan limits? ☐ Yes — Submit receive the requested dose. ☐ No	ent chart documentation and/or treatment guidelines supporting
6. For renewal requests, is there a plan for taper/discontinuation or rationale for continued use of requested drug ? \square Yes	Submit supporting documentation. $\ \square$ No
7. Is the requested agent prescribed by, or in consultation with, one of the following physician specialists? ☐ Yes ☐ No Subn. ☐ child development pediatrician ☐ child & adolescent psychiatrist ☐ general psychiatrist (only if patient is ≥ 14 years of age)	
8. Does the patient have severe symptoms related to a psychotic or neuro-developmental disorder? \square Yes – Submit medical rec	ord documentation. \square No
9. Has chart documented evidence of comprehensive evaluation and plan of care that includes non-drug therapies? \square Yes $-$ Substituting 19.	mit medical record documentation.
10. Has the patient had the following baseline and/or follow-up monitoring? Check all that apply. □ BMI and/or weight (for follow-□ fasting blood glucose or hemoglobin a1c □ fasting lipid panel □ presence of extrapyramidal symptoms (EPS) using Submit documentation of all monitoring/test results and dates.	
REQUEST FOR THERAPEUTIC DUPLICATION OF AN ATYPICAL OR TYPICAL ANTIPS	YCHOTIC
REQUEST FOR THERAPEUTIC DUPLICATION OF AN ATYPICAL OR TYPICAL ANTIPS 11. Does the patient have a medical reason for concomitant use of the requested medications? Yes – Submit documentation of the requested medications?	
11. Does the patient have a medical reason for concomitant use of the requested medications? ☐ Yes − Submit documentation o	

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or taking of any telecopy is strictly prohibited.